{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T03:20:05Z","timestamp":1778642405256,"version":"3.51.4"},"reference-count":71,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2012,2,23]],"date-time":"2012-02-23T00:00:00Z","timestamp":1329955200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Neurol Neurosci Rep"],"published-print":{"date-parts":[[2012,6]]},"DOI":"10.1007\/s11910-012-0256-9","type":"journal-article","created":{"date-parts":[[2012,2,22]],"date-time":"2012-02-22T01:00:52Z","timestamp":1329872452000},"page":"318-324","source":"Crossref","is-referenced-by-count":35,"title":["Thyroid Eye Disease: Towards an Evidence Base for Treatment in the 21st Century"],"prefix":"10.1007","volume":"12","author":[{"given":"Erin F.","family":"Gillespie","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Terry J.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raymond S.","family":"Douglas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,2,23]]},"reference":[{"key":"256_CR1","doi-asserted-by":"crossref","first-page":"3428","DOI":"10.1210\/jc.81.9.3428","volume":"81","author":"A Sorisky","year":"1996","unstructured":"Sorisky A, Pardasani D, Gagnon A, Smith TJ. Evidence of adipocyte differentiation in human orbital fibroblasts in primary culture. J Clin Endocrinol Metab. 1996;81:3428\u201331.","journal-title":"J Clin Endocrinol Metab"},{"key":"256_CR2","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1210\/er.21.2.168","volume":"21","author":"L Bartalena","year":"2000","unstructured":"Bartalena L, Pinchera A, Marcocci C. Management of Graves\u2019 ophthalmopathy: reality and perspectives. Endocr Rev. 2000;21:168\u201399.","journal-title":"Endocr Rev"},{"key":"256_CR3","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1007\/BF03350193","volume":"11","author":"WM Wiersinga","year":"1988","unstructured":"Wiersinga WM, Smit T, van der Gaag R, Koornneef L. Temporal relationship between onset of Graves\u2019 ophthalmopathy and onset of thyroidal Graves\u2019 disease. J Endocrinol Investig. 1988;11:615\u20139.","journal-title":"J Endocrinol Investig"},{"key":"256_CR4","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMcp0806317","volume":"360","author":"L Bartalena","year":"2009","unstructured":"Bartalena L, Tanda ML. Clinical practice. Graves\u2019 ophthalmopathy. N Engl J Med. 2009;360:994\u20131001.","journal-title":"N Engl J Med"},{"key":"256_CR5","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/BF03345275","volume":"27","author":"WM Wiersinga","year":"2004","unstructured":"Wiersinga WM, Prummel MF, Terwee CB. Effects of Graves\u2019 ophthalmopathy on quality of life. J Endocrinol Investig. 2004;27:259\u201364.","journal-title":"J Endocrinol Investig"},{"key":"256_CR6","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1097\/WNO.0b013e31814a5ef8","volume":"27","author":"CI Zoumalan","year":"2007","unstructured":"Zoumalan CI, Cockerham KP, Turbin RE, et al. Efficacy of corticosteroids and external beam radiation in the management of moderate to severe thyroid eye disease. J Neuro Ophthalmol. 2007;27:205\u201314.","journal-title":"J Neuro Ophthalmol"},{"key":"256_CR7","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1136\/bjo.73.8.639","volume":"73","author":"MP Mourits","year":"1989","unstructured":"Mourits MP, Koornneef L, Wiersinga WM, et al. Clinical criteria for the assessment of disease activity in Graves\u2019 ophthalmopathy: a novel approach. Br J Ophthalmol. 1989;73:639\u201344.","journal-title":"Br J Ophthalmol"},{"key":"256_CR8","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1046\/j.1365-2265.1997.2331047.x","volume":"47","author":"MP Mourits","year":"1997","unstructured":"Mourits MP, Prummel MF, Wiersinga WM, Koornneef L. Clinical activity score as a guide in the management of patients with Graves\u2019 ophthalmopathy. Clin Endocrinol (Oxf). 1997;47:9\u201314.","journal-title":"Clin Endocrinol (Oxf)"},{"key":"256_CR9","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1089\/thy.2007.0315","volume":"18","author":"L Bartalena","year":"2008","unstructured":"Bartalena L, Baldeschi L, Dickinson AJ, et al. Consensus statement of the European group on Graves\u2019 orbitopathy (EUGOGO) on management of Graves\u2019 orbitopathy. Thyroid. 2008;18:333\u201346.","journal-title":"Thyroid"},{"key":"256_CR10","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1001\/archophthalmol.2009.232","volume":"127","author":"RS Douglas","year":"2009","unstructured":"Douglas RS, Tsirbas A, Gordon M, et al. Development of criteria for evaluating clinical response in thyroid eye disease using a modified Delphi technique. Arch Ophthalmol. 2009;127:1155\u201360.","journal-title":"Arch Ophthalmol"},{"key":"256_CR11","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1210\/jc.86.2.930","volume":"86","author":"TH Brix","year":"2001","unstructured":"Brix TH, Kyvik KO, Christensen K, Hegedus L. Evidence for a major role of heredity in Graves\u2019 disease: a population-based study of two Danish twin cohorts. J Clin Endocrinol Metab. 2001;86:930\u20134.","journal-title":"J Clin Endocrinol Metab"},{"key":"256_CR12","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1001\/archinte.160.5.661","volume":"160","author":"TH Brix","year":"2000","unstructured":"Brix TH, Hansen PS, Kyvik KO, Hegedus L. Cigarette smoking and risk of clinically overt thyroid disease: a population-based twin case-control study. Arch Intern Med. 2000;160:661\u20136.","journal-title":"Arch Intern Med"},{"key":"256_CR13","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1530\/eje.0.1460153","volume":"146","author":"P Vestergaard","year":"2002","unstructured":"Vestergaard P. Smoking and thyroid disorders\u2014a meta-analysis. Eur J Endocrinol. 2002;146:153\u201361.","journal-title":"Eur J Endocrinol"},{"key":"256_CR14","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1038\/sj.eye.6702603","volume":"21","author":"J Thornton","year":"2007","unstructured":"Thornton J, Kelly SP, Harrison RA, Edwards R. Cigarette smoking and thyroid eye disease: a systematic review. Eye (Lond). 2007;21:1135\u201345.","journal-title":"Eye (Lond)"},{"key":"256_CR15","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/BF03345276","volume":"27","author":"L Hegedius","year":"2004","unstructured":"Hegedius L, Brix TH, Vestergaard P. Relationship between cigarette smoking and Graves\u2019 ophthalmopathy. J Endocrinol Investig. 2004;27:265\u201371.","journal-title":"J Endocrinol Investig"},{"key":"256_CR16","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1046\/j.1365-2265.1996.8220832.x","volume":"45","author":"J Pfeilschifter","year":"1996","unstructured":"Pfeilschifter J, Ziegler R. Smoking and endocrine ophthalmopathy: impact of smoking severity and current vs. lifetime cigarette consumption. Clin Endocrinol. 1996;45:477\u201381.","journal-title":"Clin Endocrinol"},{"key":"256_CR17","doi-asserted-by":"crossref","first-page":"632","DOI":"10.7326\/0003-4819-129-8-199810150-00010","volume":"129","author":"L Bartalena","year":"1998","unstructured":"Bartalena L, Marcocci C, Tanda ML, et al. Cigarette smoking and treatment outcomes in Graves ophthalmopathy. Ann Intern Med. 1998;129:632\u20135.","journal-title":"Ann Intern Med"},{"key":"256_CR18","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1136\/bjo.87.6.773","volume":"87","author":"A Eckstein","year":"2003","unstructured":"Eckstein A, Quadbeck B, Mueller G, et al. Impact of smoking on the response to treatment of thyroid associated ophthalmopathy. Br J Ophthalmol. 2003;87:773\u20136.","journal-title":"Br J Ophthalmol"},{"key":"256_CR19","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1001\/archinte.1990.00390170124027","volume":"150","author":"MF Prummel","year":"1990","unstructured":"Prummel MF, Wiersinga WM, Mourits MP, et al. Effect of abnormal thyroid function on the severity of Graves\u2019 ophthalmopathy. Arch Intern Med. 1990;150:1098\u2013101.","journal-title":"Arch Intern Med"},{"key":"256_CR20","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1530\/eje.0.1300494","volume":"130","author":"L Tallstedt","year":"1994","unstructured":"Tallstedt L, Lundell G, Blomgren H, Bring J. Does early administration of thyroxine reduce the development of Graves\u2019 ophthalmopathy after radioiodine treatment? Eur J Endocrinol. 1994;130:494\u20137.","journal-title":"Eur J Endocrinol"},{"key":"256_CR21","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1056\/NEJM199801083380201","volume":"338","author":"L Bartalena","year":"1998","unstructured":"Bartalena L, Marcocci C, Bogazzi F, et al. Relation between therapy for hyperthyroidism and the course of Graves\u2019 ophthalmopathy. N Engl J Med. 1998;338:73\u20138.","journal-title":"N Engl J Med"},{"key":"256_CR22","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1136\/bjo.82.7.773","volume":"82","author":"CB Terwee","year":"1998","unstructured":"Terwee CB, Gerding MN, Dekker FW, et al. Development of a disease specific quality of life questionnaire for patients with Graves\u2019 ophthalmopathy: the GO-QOL. Br J Ophthalmol. 1998;82:773\u20139.","journal-title":"Br J Ophthalmol"},{"key":"256_CR23","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1056\/NEJMoa1012985","volume":"364","author":"C Marcocci","year":"2011","unstructured":"\u2022\u2022 Marcocci C, Kahaly GJ, Krassas GE, et al. Selenium and the course of mild Graves\u2019 orbitopathy. N Engl J Med. 2011;364:1920\u201331. This is the most recent published RCT in TED. It focuses on treatment of mild disease, which propose a paradigm shift in TED management by challenging the dogma of conservative management and watchful waiting.","journal-title":"N Engl J Med"},{"key":"256_CR24","doi-asserted-by":"crossref","unstructured":"Smith TJ, Douglas RS. Pharmacotherapy: does selenium supplementation improve Graves ophthalmopathy? Nat Rev Endocrinol. 2011.","DOI":"10.1038\/nrendo.2011.128"},{"key":"256_CR25","first-page":"770","volume":"365","author":"L Sheck","year":"2011","unstructured":"Sheck L. Selenium and the course of mild Graves\u2019 orbitopathy. N Engl J Med. 2011;365:770. author reply 770\u2013771.","journal-title":"N Engl J Med"},{"key":"256_CR26","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1007\/BF03343835","volume":"24","author":"PE Macchia","year":"2001","unstructured":"Macchia PE, Bagattini M, Lupoli G, et al. High-dose intravenous corticosteroid therapy for Graves\u2019 ophthalmopathy. J Endocrinol Investig. 2001;24:152\u20138.","journal-title":"J Endocrinol Investig"},{"key":"256_CR27","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1111\/j.1742-1241.2006.01004.x","volume":"61","author":"S Aktaran","year":"2007","unstructured":"Aktaran S, Akarsu E, Erbagci I, et al. Comparison of intravenous methylprednisolone therapy vs. oral methylprednisolone therapy in patients with Graves\u2019 ophthalmopathy. Int J Clin Pract. 2007;61:45\u201351.","journal-title":"Int J Clin Pract"},{"key":"256_CR28","doi-asserted-by":"crossref","first-page":"5234","DOI":"10.1210\/jc.2005-0148","volume":"90","author":"GJ Kahaly","year":"2005","unstructured":"Kahaly GJ, Pitz S, Hommel G, Dittmar M. Randomized, single blind trial of intravenous versus oral steroid monotherapy in Graves\u2019 orbitopathy. J Clin Endocrinol Metab. 2005;90:5234\u201340.","journal-title":"J Clin Endocrinol Metab"},{"key":"256_CR29","doi-asserted-by":"crossref","first-page":"3562","DOI":"10.1210\/jc.86.8.3562","volume":"86","author":"C Marcocci","year":"2001","unstructured":"Marcocci C, Bartalena L, Tanda ML, et al. Comparison of the effectiveness and tolerability of intravenous or oral glucocorticoids associated with orbital radiotherapy in the management of severe Graves\u2019 ophthalmopathy: results of a prospective, single-blind, randomized study. J Clin Endocrinol Metab. 2001;86:3562\u20137.","journal-title":"J Clin Endocrinol Metab"},{"key":"256_CR30","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1089\/thy.2006.0267","volume":"17","author":"R Moli Le","year":"2007","unstructured":"Le Moli R, Baldeschi L, Saeed P, et al. Determinants of liver damage associated with intravenous methylprednisolone pulse therapy in Graves\u2019 ophthalmopathy. Thyroid. 2007;17:357\u201362.","journal-title":"Thyroid"},{"key":"256_CR31","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/S0140-6736(66)90954-8","volume":"1","author":"MI Garber","year":"1966","unstructured":"Garber MI. Methylprednisolone in the treatment of exophthalmos. Lancet. 1966;1:958\u201360.","journal-title":"Lancet"},{"key":"256_CR32","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1210\/jcem-56-6-1139","volume":"56","author":"L Bartalena","year":"1983","unstructured":"Bartalena L, Marcocci C, Chiovato L, et al. Orbital cobalt irradiation combined with systemic corticosteroids for Graves\u2019 ophthalmopathy: comparison with systemic corticosteroids alone. J Clin Endocrinol Metab. 1983;56:1139\u201344.","journal-title":"J Clin Endocrinol Metab"},{"key":"256_CR33","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/j.1365-2265.1987.tb00836.x","volume":"27","author":"C Marcocci","year":"1987","unstructured":"Marcocci C, Bartalena L, Panicucci M, et al. Orbital cobalt irradiation combined with retrobulbar or systemic corticosteroids for Graves\u2019 ophthalmopathy: a comparative study. Clin Endocrinol (Oxf). 1987;27:33\u201342.","journal-title":"Clin Endocrinol (Oxf)"},{"key":"256_CR34","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1136\/bjo.2004.046193","volume":"88","author":"R Ebner","year":"2004","unstructured":"Ebner R, Devoto MH, Weil D, et al. Treatment of thyroid associated ophthalmopathy with periocular injections of triamcinolone. Br J Ophthalmol. 2004;88:1380\u20136.","journal-title":"Br J Ophthalmol"},{"key":"256_CR35","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/j.1442-9071.2010.02332.x","volume":"38","author":"AA Alkawas","year":"2010","unstructured":"Alkawas AA, Hussein AM, Shahien EA. Orbital steroid injection versus oral steroid therapy in management of thyroid-related ophthalmopathy. Clin Exp Ophthalmol. 2010;38:692\u20137.","journal-title":"Clin Exp Ophthalmol"},{"key":"256_CR36","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1210\/jcem-37-2-276","volume":"37","author":"SS Donaldson","year":"1973","unstructured":"Donaldson SS, Bagshaw MA, Kriss JP. Supervoltage orbital radiotherapy for Graves\u2019 ophthalmopathy. J Clin Endocrinol Metab. 1973;37:276\u201385.","journal-title":"J Clin Endocrinol Metab"},{"key":"256_CR37","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1210\/jc.2003-030809","volume":"89","author":"MF Prummel","year":"2004","unstructured":"Prummel MF, Terwee CB, Gerding MN, et al. A randomized controlled trial of orbital radiotherapy versus sham irradiation in patients with mild Graves\u2019 ophthalmopathy. J Clin Endocrinol Metab. 2004;89:15\u201320.","journal-title":"J Clin Endocrinol Metab"},{"key":"256_CR38","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1016\/S0140-6736(00)02165-6","volume":"355","author":"MP Mourits","year":"2000","unstructured":"Mourits MP, van Kempen-Harteveld ML, Garcia MB, et al. Radiotherapy for Graves\u2019 orbitopathy: randomised placebo-controlled study. Lancet. 2000;355:1505\u20139.","journal-title":"Lancet"},{"key":"256_CR39","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1016\/S0161-6420(01)00632-7","volume":"108","author":"CA Gorman","year":"2001","unstructured":"Gorman CA, Garrity JA, Fatourechi V, et al. A prospective, randomized, double-blind, placebo-controlled study of orbital radiotherapy for Graves\u2019 ophthalmopathy. Ophthalmology. 2001;108:1523\u201334.","journal-title":"Ophthalmology"},{"key":"256_CR40","doi-asserted-by":"crossref","first-page":"2708","DOI":"10.1210\/jc.2009-0376","volume":"94","author":"H Stiebel-Kalish","year":"2009","unstructured":"\u2022 Stiebel-Kalish H, Robenshtok E, Hasanreisoglu M, et al. Treatment modalities for Graves\u2019 ophthalmopathy: systematic review and meta-analysis. J Clin Endocrinol Metab. 2009;94:2708\u201316. This is the most recent published systematic review and meta-analysis of 33 RCTs of treatment modalities for TED compared to placebo, no treatment, or other interventions.","journal-title":"J Clin Endocrinol Metab"},{"key":"256_CR41","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.ophtha.2007.10.028","volume":"115","author":"EA Bradley","year":"2008","unstructured":"Bradley EA, Gower EW, Bradley DJ, et al. Orbital radiation for graves ophthalmopathy: a report by the American Academy of Ophthalmology. Ophthalmology. 2008;115:398\u2013409.","journal-title":"Ophthalmology"},{"key":"256_CR42","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/S0360-3016(01)01699-6","volume":"51","author":"SD Marquez","year":"2001","unstructured":"Marquez SD, Lum BL, McDougall IR, et al. Long-term results of irradiation for patients with progressive Graves\u2019 ophthalmopathy. Int J Radiat Oncol Biol Phys. 2001;51:766\u201374.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"256_CR43","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1016\/j.ophtha.2003.12.054","volume":"111","author":"IM Wakelkamp","year":"2004","unstructured":"Wakelkamp IM, Tan H, Saeed P, et al. Orbital irradiation for Graves\u2019 ophthalmopathy: is it safe? a long-term follow-up study. Ophthalmology. 2004;111:1557\u201362.","journal-title":"Ophthalmology"},{"key":"256_CR44","doi-asserted-by":"crossref","first-page":"3561","DOI":"10.1210\/jc.2003-030260","volume":"88","author":"C Marcocci","year":"2003","unstructured":"Marcocci C, Bartalena L, Rocchi R, et al. Long-term safety of orbital radiotherapy for Graves\u2019 ophthalmopathy. J Clin Endocrinol Metab. 2003;88:3561\u20136.","journal-title":"J Clin Endocrinol Metab"},{"key":"256_CR45","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/S0360-3016(01)01754-0","volume":"52","author":"U Schaefer","year":"2002","unstructured":"Schaefer U, Hesselmann S, Micke O, et al. A long-term follow-up study after retro-orbital irradiation for Graves\u2019 ophthalmopathy. Int J Radiat Oncol Biol Phys. 2002;52:192\u20137.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"256_CR46","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1056\/NEJM198911163212002","volume":"321","author":"MF Prummel","year":"1989","unstructured":"Prummel MF, Mourits MP, Berghout A, et al. Prednisone and cyclosporine in the treatment of severe Graves\u2019 ophthalmopathy.[see comment]. N Engl J Med. 1989;321:1353\u20139.","journal-title":"N Engl J Med"},{"key":"256_CR47","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1111\/j.1365-2362.1986.tb01016.x","volume":"16","author":"G Kahaly","year":"1986","unstructured":"Kahaly G, Schrezenmeir J, Krause U, et al. Ciclosporin and prednisone v. prednisone in treatment of Graves\u2019 ophthalmopathy: a controlled, randomized and prospective study. Eur J Clin Investig. 1986;16:415\u201322.","journal-title":"Eur J Clin Investig"},{"key":"256_CR48","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1677\/jme.0.0250063","volume":"25","author":"D Pasquali","year":"2000","unstructured":"Pasquali D, Vassallo P, Esposito D, et al. Somatostatin receptor gene expression and inhibitory effects of octreotide on primary cultures of orbital fibroblasts from Graves\u2019 ophthalmopathy. J Mol Endocrinol. 2000;25:63\u201371.","journal-title":"J Mol Endocrinol"},{"key":"256_CR49","doi-asserted-by":"crossref","first-page":"5910","DOI":"10.1210\/jc.2004-0697","volume":"89","author":"AJ Dickinson","year":"2004","unstructured":"Dickinson AJ, Vaidya B, Miller M, et al. Double-blind, placebo-controlled trial of octreotide Long-Acting Repeatable (LAR) in thyroid-associated ophthalmopathy. J Clin Endocrinol Metab. 2004;89:5910\u20135.","journal-title":"J Clin Endocrinol Metab"},{"key":"256_CR50","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1210\/jc.2004-1334","volume":"90","author":"JL Wemeau","year":"2005","unstructured":"Wemeau JL, Caron P, Beckers A, et al. Octreotide (long-acting release formulation) treatment in patients with graves\u2019 orbitopathy: clinical results of a four-month, randomized, placebo-controlled, double-blind study. J Clin Endocrinol Metab. 2005;90:841\u20138.","journal-title":"J Clin Endocrinol Metab"},{"key":"256_CR51","doi-asserted-by":"crossref","first-page":"4817","DOI":"10.1210\/jc.2006-1105","volume":"91","author":"MN Stan","year":"2006","unstructured":"Stan MN, Garrity JA, Bradley EA, et al. Randomized, double-blind, placebo-controlled trial of long-acting release octreotide for treatment of Graves\u2019 ophthalmopathy. J Clin Endocrinol Metab. 2006;91:4817\u201324.","journal-title":"J Clin Endocrinol Metab"},{"key":"256_CR52","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/BF03344124","volume":"29","author":"TC Chang","year":"2006","unstructured":"Chang TC, Liao SL. Slow-release lanreotide in Graves\u2019 ophthalmopathy: a double-blind randomized, placebo-controlled clinical trial. J Endocrinol Investig. 2006;29:413\u201322.","journal-title":"J Endocrinol Investig"},{"key":"256_CR53","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1053\/sonc.2002.30156","volume":"29","author":"DG Maloney","year":"2002","unstructured":"Maloney DG, Smith B, Rose A. Rituximab: mechanism of action and resistance. Semin Oncol. 2002;29:2\u20139.","journal-title":"Semin Oncol"},{"key":"256_CR54","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1530\/eje.1.02119","volume":"154","author":"M Salvi","year":"2006","unstructured":"Salvi M, Vannucchi G, Campi I, et al. Efficacy of rituximab treatment for thyroid-associated ophthalmopathy as a result of intraorbital B-cell depletion in one patient unresponsive to steroid immunosuppression. Eur J Endocrinol. 2006;154:511\u20137.","journal-title":"Eur J Endocrinol"},{"key":"256_CR55","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1530\/eje.1.02325","volume":"156","author":"M Salvi","year":"2007","unstructured":"\u2022\u2022 Salvi M, Vannucchi G, Campi I, et al. Treatment of Graves\u2019 disease and associated ophthalmopathy with the anti-CD20 monoclonal antibody rituximab: an open study. Eur J Endocrinol. 2007;156:33\u201340. This is the first article to present a treatment modality, specifically rituximab, that is more effective than IV methylprednisolone in reducing CAS in patients with active TED.","journal-title":"Eur J Endocrinol"},{"key":"256_CR56","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.ophtha.2009.05.029","volume":"117","author":"D Khanna","year":"2010","unstructured":"Khanna D, Chong KK, Afifiyan NF, et al. Rituximab treatment of patients with severe, corticosteroid-resistant thyroid-associated ophthalmopathy. Ophthalmology. 2010;117:133\u2013139 e132.","journal-title":"Ophthalmology"},{"key":"256_CR57","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1097\/IOP.0b013e3181c4dfde","volume":"26","author":"RZ Silkiss","year":"2010","unstructured":"Silkiss RZ, Reier A, Coleman M, Lauer SA. Rituximab for thyroid eye disease. Ophthalmic Plast Reconstr Surg. 2010;26:310\u20134.","journal-title":"Ophthalmic Plast Reconstr Surg"},{"key":"256_CR58","unstructured":"El Fassi D, Nielsen CH, Junker P, et al. Systemic adverse events following rituximab therapy in patients with Graves\u2019 disease. J Endocrinol Investig. 2010."},{"key":"256_CR59","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1038\/sj.eye.6701768","volume":"19","author":"D Paridaens","year":"2005","unstructured":"Paridaens D, van den Bosch WA, van der Loos TL, et al. The effect of etanercept on Graves\u2019 ophthalmopathy: a pilot study. Eye (Lond). 2005;19:1286\u20139.","journal-title":"Eye (Lond)"},{"key":"256_CR60","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1046\/j.1365-2249.1996.d01-854.x","volume":"106","author":"G Kahaly","year":"1996","unstructured":"Kahaly G, Pitz S, Muller-Forell W, Hommel G. Randomized trial of intravenous immunoglobulins versus prednisolone in Graves\u2019 ophthalmopathy. Clin Exp Immunol. 1996;106:197\u2013202.","journal-title":"Clin Exp Immunol"},{"key":"256_CR61","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1089\/thy.1997.7.579","volume":"7","author":"L Baschieri","year":"1997","unstructured":"Baschieri L, Antonelli A, Nardi S, et al. Intravenous immunoglobulin versus corticosteroid in treatment of Graves\u2019 ophthalmopathy. Thyroid. 1997;7:579\u201385.","journal-title":"Thyroid"},{"key":"256_CR62","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1002\/jca.20244","volume":"25","author":"J Cap","year":"2010","unstructured":"Cap J, Ceeova V, Skacha M, et al. Plasma filtration in the treatment of Graves\u2019 ophthalmopathy: a randomized study. J Clin Apher. 2010;25:209\u201315.","journal-title":"J Clin Apher"},{"key":"256_CR63","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1016\/0002-9149(94)90828-1","volume":"73","author":"Y Adler","year":"1994","unstructured":"Adler Y, Zandman-Goddard G, Ravid M, et al. Usefulness of colchicine in preventing recurrences of pericarditis. Am J Cardiol. 1994;73:916\u20137.","journal-title":"Am J Cardiol"},{"key":"256_CR64","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1007\/s10165-009-0200-2","volume":"19","author":"F Davatchi","year":"2009","unstructured":"Davatchi F, Sadeghi Abdollahi B, Tehrani Banihashemi A, et al. Colchicine versus placebo in Behcet\u2019s disease: randomized, double-blind, controlled crossover trial. Mod Rheumatol. 2009;19:542\u20139.","journal-title":"Mod Rheumatol"},{"key":"256_CR65","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1007\/s11926-002-0073-2","volume":"4","author":"Y Molad","year":"2002","unstructured":"Molad Y. Update on colchicine and its mechanism of action. Curr Rheumatol Rep. 2002;4:252\u20136.","journal-title":"Curr Rheumatol Rep"},{"key":"256_CR66","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1590\/S0004-27492006000600006","volume":"69","author":"FJ Stamato","year":"2006","unstructured":"Stamato FJ, Maciel RM, Manso PG, et al. Colchicine in the treatment of the inflammatory phase of Graves\u2019 ophthalmopathy: a prospective and randomized trial with prednisone. Arq Bras Oftalmol. 2006;69:811\u20136.","journal-title":"Arq Bras Oftalmol"},{"key":"256_CR67","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1530\/eje.0.1480491","volume":"148","author":"MF Prummel","year":"2003","unstructured":"Prummel MF, Bakker A, Wiersinga WM, et al. Multi-center study on the characteristics and treatment strategies of patients with Graves\u2019 orbitopathy: the first European Group on Graves\u2019 Orbitopathy experience. Eur J Endocrinol. 2003;148:491\u20135.","journal-title":"Eur J Endocrinol"},{"key":"256_CR68","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1111\/j.1365-2265.2005.02345.x","volume":"63","author":"IM Wakelkamp","year":"2005","unstructured":"Wakelkamp IM, Baldeschi L, Saeed P, et al. Surgical or medical decompression as a first-line treatment of optic neuropathy in Graves\u2019 ophthalmopathy? a randomized controlled trial. Clin Endocrinol (Oxf). 2005;63:323\u20138.","journal-title":"Clin Endocrinol (Oxf)"},{"key":"256_CR69","unstructured":"National Organization for Rare Disorders: Graves\u2019 Disease. Available at http:\/\/www.rarediseases.org\/search\/rdbdetail_abstract.html?disname=Graves%27%20Disease Accessed March 2011."},{"key":"256_CR70","unstructured":"US National Institutes of Health: Trial of Rituximab for Graves\u2019 Ophthalmopathy. Available at http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00595335 . Accessed March 2011."},{"key":"256_CR71","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1016\/j.ajo.2009.07.034","volume":"148","author":"JD Perry","year":"2009","unstructured":"Perry JD, Feldon SE. Rationale for radiotherapy in thyroid eye disease. Am J Ophthalmol. 2009;148:818\u20139.","journal-title":"Am J Ophthalmol"}],"container-title":["Current Neurology and Neuroscience Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11910-012-0256-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11910-012-0256-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11910-012-0256-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,24]],"date-time":"2019-06-24T02:31:32Z","timestamp":1561343492000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11910-012-0256-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,2,23]]},"references-count":71,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012,6]]}},"alternative-id":["256"],"URL":"https:\/\/doi.org\/10.1007\/s11910-012-0256-9","relation":{},"ISSN":["1528-4042","1534-6293"],"issn-type":[{"value":"1528-4042","type":"print"},{"value":"1534-6293","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,2,23]]}}}